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Abstract
Background: We evaluated the antitumor activity and safety of avelumab, a human anti–PD-L1 IgG1 antibody, as
first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal
cancer (GC/GEJC) previously treated with chemotherapy.
Methods: In a phase 1b expansion cohort, patients without (1 L-mn) or with (2 L) disease progression following first-line
chemotherapy for advanced GC/GEJC received avelumab 10mg/kg intravenously every 2 weeks. Endpoints included best
overall response, progression-free survival (PFS), overall survival (OS), and safety.
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Results: Overall, 150 patients were enrolled (1 L-mn, n= 90; 2 L, n= 60) and median follow-up in the 1 L-mn and 2 L
subgroups was 36.0 and 33.7months, respectively. The confirmed objective response rate was 6.7% in both subgroups
(95% CI, 2.5–13.9% and 1.8–16.2%, respectively), including complete responses in 2.2% of the 1 L-mn subgroup (n= 2). In
the 1 L-mn and 2 L subgroups, median duration of response was 21.4 months (95% CI, 4.0–not estimable) and 3.5months
(95% CI, 2.8–8.3) and disease control rates were 56.7 and 28.3%, respectively. Median PFS in the 1 L-mn and 2 L subgroups
was 2.8months (95% CI, 2.3–4.1) and 1.4months (95% CI, 1.3–1.5), with 6-month PFS rates of 23.0% (95% CI, 14.7–32.4%)
and 7.9% (95% CI, 2.6–17.2%), and median OS was 11.1months (95% CI, 8.9–13.7) and 6.6 months (95% CI, 5.4–9.4),
respectively. In the 1 L-mn subgroup, median OS measured from start of 1 L chemotherapy was 18.7 months
(95% CI, 15.4–20.6). Across both subgroups, 20.7% had an infusion-related reaction of any grade. Other common
treatment-related adverse events (TRAEs) of any grade included fatigue (10.0%) and nausea (6.7%). Treatment-related
serious adverse events occurred in 4.0% of patients. Overall, 8.7% had a grade≥3 TRAE, including 1 treatment-related death.
Conclusion: Avelumab showed clinical activity and an acceptable safety profile in patients with GC/GEJC.
Trial registration: ClinicalTrials.gov NCT01772004; registered 21 January 2013.
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Background
Gastric cancer (GC) is an aggressive disease that repre-
sents the third leading cause of cancer-related death
worldwide [1]. Gastroesophageal junction cancer (GEJC)
has similar biology, prognosis, and treatment guidelines
as GC [2, 3]. First-line (1 L) standard of care for ad-
vanced inoperable GC/GEJC is based on combination
fluoropyrimidine and platinum treatment, with trastuzu-
mab added for HER2+ tumors. Second-line (2 L) options
include regimens based on irinotecan, taxanes, and/or
ramucirumab [2, 3]. However, cytotoxic regimens are
associated with cumulative toxicity that may restrict
long-term treatment, resulting in limited duration of re-
sponse and overall survival (OS). Maintenance therapy,
ie, continued treatment with an agent administered in
the 1 L induction regimen or sequential treatment with a
different agent until progression (switch maintenance),
has the potential to extend durations of response and
OS, particularly when an agent with a different mechan-
ism of action is employed, while avoiding potential addi-
tive toxicity associated with further chemotherapy or
combination treatment. As such, maintenance therapy
has become an established strategy for several advanced
tumors [4, 5]. Although the role of maintenance therapy
in treating GC/GEJC is less well defined, observational
and retrospective studies of maintenance fluoropyrimidine
treatment in advanced GC/GEJC have shown that this
approach is feasible and may improve progression-free
survival (PFS) compared with observation alone [6–8].
In recent years, much attention has been focused on
anticancer therapies that activate the immune response. In
a randomized phase 2 study of patients with advanced
GC/GEJC, switch-maintenance ipilimumab (anti–CTLA-4)
after 1 L chemotherapy did not improve immune-related
PFS or OS compared with best supportive care, which in-
cluded continued fluoropyrimidine chemotherapy in most
patients [9]. PD-L1 is a key therapeutic target for reactivat-
ing antitumor immune responses [10]. Additionally, PD-L1
is expressed in ≈30 to 60% of GC/GEJC specimens, with a
higher frequency seen in certain pathological and genomic
subtypes [11]. Immunotherapy with anti–PD-1 antibodies
has been associated with durable antitumor responses
in early-phase studies of patients with GC/GEJC
[10, 12, 13].
Avelumab is a human anti–PD-L1 monoclonal antibody
that has been approved in various countries for the treat-
ment of metastatic Merkel cell carcinoma and in the United
States and Canada for the treatment of advanced urothelial
carcinoma progressing after platinum-containing chemo-
therapy. In phase 1 and 2 studies across various advanced
cancers, avelumab has demonstrated a tolerable safety pro-
file and durable antitumor activity [14–16]. In preclinical
studies, avelumab activated both adaptive and innate im-
mune effector cells [17, 18], suggesting an additional mech-
anism of action compared with other approved anti–PD-1/
PD-L1 antibodies.
To investigate the efficacy and safety of avelumab in
the treatment of advanced GC/GEJC, we enrolled a
cohort of patients in the phase 1 JAVELIN Solid Tumor
trial. Patients were enrolled following 1 L chemotherapy;
those without disease progression received avelumab as
1 L switch maintenance (1 L-mn subgroup), and those
with disease progression received avelumab as 2 L treat-
ment (2 L subgroup). To our knowledge, this is the first
study of an anti–PD-L1 agent administered as switch-
maintenance therapy in this disease.
Methods
Study design and patients
JAVELIN Solid Tumor (NCT01772004) is an inter-
national, open-label, phase 1 trial. In the phase 1b, non-
randomized expansion cohort reported here, eligible
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patients had histologically confirmed, unresectable,
locally advanced or metastatic GC/GEJC, and previous
treatment with 1 L combination chemotherapy; patients
with prior neoadjuvant platinum-based doublet or triplet
chemotherapy who were not candidates for surgery were
also eligible. Patients should not have received >1 line of
prior treatment for metastatic disease, and patients with
prior checkpoint inhibitor or trastuzumab treatment
were ineligible (Additional file 1: Table S1). Patients in
the 2 L subgroup were not permitted to have received
anticancer treatment within 28 days before the start of
study treatment, whereas in the 1 L-mn subgroup,
patients were permitted to be enrolled within 28 days if
all toxicity from prior therapy had resolved to grade ≤1.
A fresh or archival tumor specimen was required, but
patients were not preselected based on PD-L1 status
(ie, all-comer design). Patients were enrolled in accordance
with an approved protocol, international standards of good
clinical practice, and institutional safety monitoring, and
written informed consent was obtained. The study protocol
was approved by the institutional review board or
independent ethics committee at each center.
Procedures and assessments
Patients received avelumab 10mg/kg intravenously every
2 weeks until confirmed disease progression, unaccept-
able toxicity, or protocol-based criteria for withdrawal
[15]. Premedication with diphenhydramine and
acetaminophen was required 30 to 60min before all
avelumab infusions.
Safety was assessed at each biweekly trial visit and in-
cluded assessment of adverse events (AEs), physical
examination, clinical laboratory tests (hematology, hep-
atic panels, and serum chemistry), and documentation of
concurrent medications. AEs and laboratory abnormal-
ities were classified and graded according to National
Cancer Institute Common Terminology Criteria for
Adverse Events version 4.0. A serious AE (SAE) was de-
fined as any untoward event that was life-threatening,
required hospitalization, resulted in disability, was a con-
genital anomaly, or resulted in death. Immune-related
AEs were identified using a prespecified list of Medical
Dictionary for Regulatory Activities terms plus medical
review. Clinical activity was assessed by investigators
using Response Evaluation Criteria in Solid Tumors
version 1.1. Radiographic tumor assessments were
performed at baseline and every 6 weeks. In patients
achieving a partial response (PR) or complete response
(CR), a confirmatory CT or MRI scan was done ≥28 days
later (preferably at the scheduled 6-week interval).
PD-L1 expression was assessed in tumor cells using a
proprietary immunohistochemistry assay (PD-L1 IHC
73-10; Dako, Carpinteria, CA), as described previously
[15, 19]; in this report, PD-L1 status was defined using
cutoffs of ≥1% of tumor cells positive for partial or
complete membrane PD-L1 staining of any intensity. HER2
and microsatellite status were recorded retrospectively
from medical records when available.
Outcomes
Primary endpoints for the entire JAVELIN Solid Tumor
trial were dose-limiting toxicities during the first 3 weeks
of treatment in the phase 1a dose-escalation part
(reported previously [20]) and confirmed best overall
response adjudicated by independent review in specified
efficacy expansion cohorts (not including the GC/GEJC
cohort reported here). Secondary endpoints assessed in
the current cohort included investigator-assessed best
overall response, duration of response, PFS, OS, safety,
and evaluation of PD-L1 expression [15].
Statistical methods
Enrollment of 150 patients was planned for this cohort
based on the anticipated sample size required to estimate
and provide 95% Clopper-Pearson confidence intervals
(CIs) for potential objective response rates (ORR; propor-
tion of patients with a confirmed CR or PR; eg, 10% [5.7–
16.0%] for 15 responders or 20% [13.9–27.3%] for 30
responders). Safety and antitumor activity were analyzed
in all patients who received ≥1 dose of avelumab.
Time-to-event endpoints (PFS, OS, duration of response,
and duration of follow-up) were estimated using the
Kaplan–Meier method and CIs for the median were
calculated using the Brookmeyer–Crowley method.
Results
Patients
Between 13 February 2014 and 11 August 2015, 150
patients with histologically confirmed GC/GEJC were
enrolled, including 90 without disease progression after
1 L chemotherapy (1 L-mn subgroup) and 60 with
progressive disease (2 L subgroup), per investigator
assessment (Table 1). In the 1 L-mn subgroup, 27.8%
had achieved a PR with prior chemotherapy; in the 2 L
subgroup, prior responses were PR in 13.3% and CR in
1.7%. The median interval between end of prior chemo-
therapy and start of avelumab was 45 days (1 L-mn
subgroup) and 77 days (2 L subgroup). Across both
subgroups, 30.7% had PD-L1+ tumors.
At data cutoff (30 September 2017), patients in the 1
L-mn and 2 L subgroups had received a median (range)
of 7 (1–79) and 4.5 (1–44) avelumab doses, and median
duration of treatment was 3.2 months (interquartile
range [IQR], 1.4–6.1) and 2.2 months (IQR, 1.4–5.2),
respectively. Median duration of follow-up was 36.0
months (IQR, 33.7–37.7) in the 1 L-mn subgroup and
33.7 months (IQR, 27.9–34.9) in the 2 L subgroup. In
both subgroups, the most common reason for treatment
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discontinuation was disease progression (1 L-mn, 75.6%;
2 L, 71.7%); other reasons were AE (13.3%, 10.0%), death
(3.3%, 8.3%), withdrawal of consent (1.1%, 6.7%), loss to
follow-up (0%, 1.7%), protocol noncompliance (1.1%, 0%),
and physician decision (0%, 1.7%). Five patients remained
on avelumab treatment at data cutoff, all in the 1 L-mn
subgroup (5.6%).
Antitumor activity: 1 L-mn subgroup
The confirmed ORR (additional effect after the end of
chemotherapy) was 6.7% (n = 6; 95% CI, 2.5–13.9%)
(Additional file 1: Table S2). Notably, 2 patients (2.2%)
had a CR; both patients were Asian and had stable dis-
ease (SD) as best response to prior chemotherapy, and
PD-L1 status was positive in 1 patient and not evaluable
in the other. Four patients (4.4%) had a PR, which repre-
sented additional tumor shrinkage following prior
chemotherapy; best response to prior chemotherapy in
these patients was PR (n = 2) and SD (n = 2) (Additional
file 1: Table S3). Forty-five patients (50.0%) had SD of
any duration as best response (disease control rate,
56.7%). Early and durable responses were observed
(Fig. 1a and Additional file 1: Figure S1A), with a median
time to response of 1.4 months (IQR, 1.3–4.1), a median
duration of response of 21.4 months (95% CI, 4.0–not
estimable), and an estimated 66.7% (95% CI, 19.5–
90.4%) of responses lasting ≥6 months. Responses were
Table 1 Baseline characteristics in the first-line switch-maintenance
and second-line subgroups
Characteristics 1 L-mn subgroup
(n = 90)
2 L subgroup
(n = 60)
Median age (IQR), years 59 (52.0–67.0) 62.5 (51.5–66.0)
Sex, n (%)
Male 68 (75.6) 46 (76.7)
Female 22 (24.4) 14 (23.3)
ECOG PS, n (%)
0 37 (41.1) 23 (38.3)
1 53 (58.9) 37 (61.7)
Geographic region, n (%)
North America 31 (34.4) 32 (53.3)
Asia 34 (37.8) 10 (16.7)
Europe 25 (27.8) 18 (30.0)
Race, n (%)
White 44 (48.9) 36 (60.0)
Asian 35 (38.9) 13 (21.7)
Black 4 (4.4) 4 (6.7)
Other 7 (7.8) 7 (11.7)
Histology, n (%)
Tubular 18 (20.0) 3 (5.0)
Signet ring 17 (18.9) 13 (21.7)
Mucinous 4 (4.4) 4 (6.7)
Papillary 1 (1.1) 0
Other/not specified 1 (1.1) 0
Unknown 37 (41.1) 39 (65.0)
PD-L1 expression status based on ≥1% cutoff on tumor cells, n (%)
PD-L1+ 26 (28.9) 20 (33.3)
PD-L1− 51 (56.7) 25 (41.7)
Not evaluable 13 (14.4) 15 (25.0)
HER2 status, n (%)
HER2− 62 (68.9) 29 (48.3)
HER2+ 4 (4.4) 5 (8.3)
Unknown 24 (26.7) 26 (43.3)
Microsatellite status, n (%)
Low 1 (1.1) 0
Stable 21 (23.3) 17 (28.3)
High 2 (2.2) 2 (3.3)
Unknown 66 (73.3) 41 (68.3)
Prior gastrectomy, n (%) 24 (26.7) 14 (23.3)
Metastatic disease status at study entry, n (%)
M0 5 (5.6) 2 (3.3)
M1 85 (94.4) 58 (96.7)
Tumor size at baselinea
Median (IQR), mm 33 (19–52) 44 (25–69.5)
Unknown, n (%) 1 (1.1) 1 (1.7)
Table 1 Baseline characteristics in the first-line switch-maintenance
and second-line subgroups (Continued)
Characteristics 1 L-mn subgroup
(n = 90)
2 L subgroup
(n = 60)
Best response to prior anticancer therapy, n (%)
Complete response 0 1 (1.7)
Partial response 25 (27.8) 8 (13.3)
Stable disease 59 (65.6) 23 (38.3)
Progressive disease 0 22 (36.7)
Not evaluable or unknown 6 (6.7) 5 (8.3)
Prior anticancer therapy
(any setting), n (%)
90 (100) 60 (100)
Number of prior lines of anticancer therapy for metastatic or locally
advanced disease, n (%)
0 1 (1.1) 5 (8.3)
1 87 (96.7) 53 (88.3)
2 2 (2.2) 1 (1.7)
Unknown 0 1 (1.7)
Median prior lines (range) 1.0 (0–2) 1.0 (0–2)
Interval from end of prior chemotherapy to start of avelumab therapy
Median (IQR), days 45 (35–64) 77 (49–135)
Data missing, n (%) 8 (8.9) 15 (25.0)
aSum of the longest diameters of target lesions
Abbreviations: 1 L-mn first-line switch-maintenance, 2 L second line, ECOG PS
Eastern Cooperative Oncology Group performance status, IQR interquartile range
Chung et al. Journal for ImmunoTherapy of Cancer            (2019) 7:30 Page 4 of 10
ongoing at data cutoff in 2 patients, including 1 patient
with a CR. In evaluable patients with PD-L1+ or PD-L1−
tumors, confirmed ORR was 7.7% (2/26; 95% CI, 0.9–
25.1%) vs 3.9% (2/51; 95% CI, 0.5–13.5%). Of 81 patients
evaluable for change in size of target lesions, 13 (16.0%)
had shrinkage of ≥30% and 37 (45.7%) had shrinkage of
any level (Additional file 1: Figure S2A). No correlation
was seen between response to prior chemotherapy and
tumor shrinkage on avelumab.
Two patients had prolonged shrinkage in target
lesions with avelumab after documented progressive
disease (due to >30% increase in target lesion size vs
baseline at weeks 7–13 in 1 patient and a new lesion in
the other patient), suggestive of pseudoprogression.
Duration of avelumab treatment in these 2 patients was
36.2months (ongoing) and 23.5months, respectively.
Another patient had SD before disease progression at
week 13 (due to a new lesion), followed by a 100%
reduction in target lesions sustained for >6 months.
Median PFS and OS measured from start of avelumab
therapy (ie, not including prior chemotherapy) were 2.8
months (95% CI, 2.3–4.1) and 11.1 months (95% CI,
8.9–13.7), respectively. The 6-month and 12-month PFS
rates were 23.0% (95% CI, 14.7–32.4%) and 13.0% (95%
CI, 6.6–21.6%), respectively, and the 12-month OS rate
was 46.2% (95% CI, 35.6–56.1%) (Fig. 2a and b). In
patients from Asian and non-Asian countries, median
OS was 12.4 months (95% CI, 9.7–20.0) and 9.4 months
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Fig. 1 Change in sum of target lesion diameters over time with avelumab in evaluable patients. a First-line switch-maintenance subgroup (n = 81).
b Second-line subgroup (n = 52). Color coding is based on best overall response per Response Evaluation Criteria in Solid Tumors version 1.1. Dotted
lines indicate the 3-month timepoint and changes in target lesion size of −30, 0, and +20%
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(95% CI, 7.4–13.7), respectively. Median OS measured
from start of 1 L chemotherapy was 18.7 months (95%
CI, 15.4–20.6) overall (Fig. 2c), and 20.6 months (95%
CI, 17.1–28.1) and 15.8 months (95% CI, 12.3–19.9) in
patients from Asian and non-Asian countries, respect-
ively. In PD-L1+ and PD-L1− subgroups, median PFS
was 3.0 (95% CI, 1.4–4.1) and 2.7 (95% CI, 1.4–3.6) months
(hazard ratio [HR], 0.844 [95% CI, 0.505–1.411]) and
median OS was 15.9 (95% CI, 11.4–20.7) and 10.4 (95% CI,
8.3–12.4) months (HR, 0.588 [95% CI, 0.342–1.009]),
respectively (Additional file 1: Figures S3A and S4A).
Antitumor activity: 2 L subgroup
The ORR was 6.7% (95% CI, 1.8–16.2%; PR in 4 patients),
and the disease control rate was 28.3% (13 patients [21.7%]
had SD as best response) (Additional file 1: Table S2). Me-
dian time to and duration of response were 2.0months
(IQR, 1.3–2.7) and 3.5months (95% CI, 2.8–8.3), respect-
ively. An estimated 25.0% (95% CI, 0.9–66.5%) of responses
lasted ≥6months (Fig. 1b and Additional file 1: Figure S1B).
Of 52 evaluable patients, 7 (13.5%) had target lesion shrink-
age of ≥30% and 16 (30.8%) had shrinkage of any level
(Additional file 1: Figure S2B). Median PFS was 1.4months
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Fig. 2 Kaplan–Meier estimates of progression-free survival (PFS) and overall survival (OS). a PFS from start of avelumab in the first-line switch-
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(95% CI, 1.3–1.5), and 6-month and 12-month PFS rates
were 7.9% (95% CI, 2.6–17.2%) and 2.0% (95% CI, 0.2–
9.1%), respectively (Fig. 2d). Median OS was 6.6months
(95% CI, 5.4–9.4), and the 12-month OS rate was 25.6%
(95% CI, 14.9–37.6%) (Fig. 2e). In patients from Asian and
non-Asian countries, median OS was 8.3months (95% CI,
2.0–10.4) and 6.3months (95% CI, 4.3–9.4), respectively. No
significant difference was seen in PFS and OS based on
PD-L1 status (Additional file 1: Figures S3B and S4B).
Safety
Across both subgroups, 85 of 150 patients (56.7%) had a
treatment-related AE (TRAE) of any grade, including 57
of 90 (63.3%) in the 1 L-mn subgroup and 28 of 60
(46.7%) in the 2 L subgroup. Patterns of TRAEs were
similar in both subgroups (Table 2 and Additional file 1:
Table S4). Overall, infusion-related reactions and related
symptoms occurred in 20.7%. Time to onset of
infusion-related reaction was first or second infusion in
29 of 31 cases (93.5%). Other common TRAEs (any
grade in ≥5%) were fatigue (10.0%), nausea (6.7%), chills
(6.0%), and pruritus (5.3%). Thirteen patients (8.7%) had
a grade ≥3 TRAE (1 L-mn subgroup, 8 [8.9%]; 2 L
subgroup, 5 [8.3%]), most commonly fatigue, asthenia,
anemia, and elevated lipase (n = 2 each; 1.3%). One
patient (0.7%) had a grade 3 infusion-related reaction
(1 L-mn subgroup). Two patients (both 2 L subgroup) had
a grade 4 TRAE: elevated lipase (n = 1) and decreased
platelet count (n = 1). Overall, 81 patients (54.0%) had a
SAE, which was related to treatment in 6 patients (4.0%; 3
in each subgroup). One treatment-related death occurred
(1 L-mn subgroup) in a patient with peritoneal metastases
and ascites at study entry who developed grade 5
autoimmune hepatitis and hepatic failure. Twenty-three
patients (15.3%) had an immune-related AE, including
grade ≥3 in 3 patients (2.0%): colitis (grade 3, 1 L-mn),
autoimmune hepatitis/hepatic failure (grade 5, 1 L-mn),
and adrenal insufficiency (grade 3, 2 L). Avelumab was
permanently discontinued following a TRAE in 8 patients
(5.3% overall; 1 L-mn: 6 [6.7%]; 2 L: 2 [3.3%]), of whom 3
(2.0%) discontinued because of an infusion-related
reaction.
Table 2 Any-grade TRAEs occurring in ≥10% of patients or grade ≥3 in any patient and infusion-related reactions in the first-line
switch-maintenance or second-line subgroup
Patients, n (%) 1 L-mn subgroup (n = 90) 2 L subgroup (n = 60)
Any grade Grade 3 Grade 4 Grade 5 Any grade Grade 3 Grade 4 Grade 5
Any TRAEa 57 (63.3) 7 (7.8) 0 1 (1.1) 28 (46.7) 3 (5.0) 2 (3.3) 0
Fatigue 10 (11.1) 2 (2.2) 0 0 5 (8.3) 0 0 0
Decreased appetite 3 (3.3) 0 0 0 2 (3.3) 1 (1.7) 0 0
Asthenia 1 (1.1) 0 0 0 3 (5.0) 2 (3.3) 0 0
Colitis 2 (2.2) 1 (1.1) 0 0 0 0 0 0
Elevated amylase 2 (2.2) 0 0 0 1 (1.7) 1 (1.7) 0 0
Elevated lipase 2 (2.2) 1 (1.1) 0 0 1 (1.7) 0 1 (1.7) 0
Elevated γ-glutamyltransferase 2 (2.2) 1 (1.1) 0 0 0 0 0 0
Anemia 1 (1.1) 1 (1.1) 0 0 1 (1.7) 1 (1.7) 0 0
Decreased platelet count 1 (1.1) 1 (1.1) 0 0 1 (1.7) 0 1 (1.7) 0
Abdominal pain 1 (1.1) 1 (1.1) 0 0 0 0 0 0
Adrenal insufficiency 1 (1.1) 0 0 0 1 (1.7) 1 (1.7) 0 0
Autoimmune hepatitisb 1 (1.1) 0 0 1 (1.1) 0 0 0 0
Decreased hemoglobin 1 (1.1) 1 (1.1) 0 0 0 0 0 0
Hepatic failureb 1 (1.1) 0 0 1 (1.1) 0 0 0 0
Hyperglycemia 1 (1.1) 1 (1.1) 0 0 0 0 0 0
Hypokalemia 1 (1.1) 1 (1.1) 0 0 0 0 0 0
Peripheral motor neuropathy 1 (1.1) 1 (1.1) 0 0 0 0 0 0
Infusion-related reactionc 20 (22.2) 1 (1.0) 0 0 11 (18.3) 0 0 0
aThe incidence of treatment-related infusion-related reaction based on the single MedDRA preferred term is not listed
bOccurred in the same patient
cIncludes adverse events categorized as infusion-related reaction, drug hypersensitivity, or hypersensitivity reaction that occurred on the day of infusion or day
after infusion, in addition to signs and symptoms of infusion-related reaction that occurred on the same day of infusion and resolved within 2 days (including
adverse events classified by investigators as related or unrelated to treatment)
1 L-mn first-line switch-maintenance, 2 L second line, TRAE treatment-related adverse event
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Discussion
In this single-arm phase 1b cohort of 150 patients with
previously treated advanced GC/GEJC, avelumab
showed evidence of durable antitumor activity as 1 L-mn
and 2 L therapy. The ORR was 6.7% in both subgroups,
although median durations of response were 21.4
months in the 1 L-mn subgroup and 3.5 months in the 2
L subgroup. Remarkably, 2 patients (2.2%) in the 1 L-mn
subgroup had a CR after achieving only SD on prior
chemotherapy. Avelumab showed a tolerable safety
profile, including a low rate of grade ≥3 TRAEs (8.7%)
and immune-related AEs (any grade, 15.3%; grade ≥3,
2.0%), similar to observations in other tumor types [21].
Detailed guidance for recognizing and managing
immune-related AEs with this class of agents have been
published by consensus groups [22, 23]. The incidence
of TRAEs of any grade was higher in the 1 L-mn sub-
group compared with the 2 L subgroup (63.3% vs
46.7%), which may be due to the longer treatment dur-
ation and shorter interval from end of prior chemother-
apy to start of avelumab in the 1 L-mn subgroup,
although the incidence of grade ≥3 TRAEs was similar in
both subgroups (8.9% vs 8.3%, respectively).
Approximately 70% of patients achieve a response or
SD with standard 1 L chemotherapy [24, 25]; however,
duration of OS is usually short [2, 3]. In the 1 L-mn sub-
group, median PFS was 2.8 months (6-month rate,
23.0%), median OS measured from the start of avelumab
was 11.1 months (12-month rate, 46.2%), and median
OS measured from the start of prior chemotherapy was
18.7 months. Thus, the OS seen in the 1 L-mn subgroup,
which enrolled patients without disease progression fol-
lowing chemotherapy, is encouraging for this subgroup
of patients. Administering immunotherapy sequentially
after completion of 1 L chemotherapy may enhance the
immunostimulatory effects of chemotherapy while redu-
cing the toxicity that may result when anti–PD-1 anti-
bodies are administered in combination with other
agents (eg, chemotherapy or ipilimumab) [26, 27]. To
further assess this strategy, a randomized phase 3 trial is
comparing avelumab switch-maintenance treatment with
continuation of 1 L platinum-based chemotherapy in
patients with advanced GC/GEJC (JAVELIN Gastric 100;
NCT02625610).
Several early-phase studies assessed anti–PD-1 monother-
apy in patients with chemotherapy-treated (later-line) GC/
GEJC outside of the maintenance setting [12, 13, 27, 28],
and median PFS and OS reported in non–PD-L1–selected
populations were 2.0months and 5.5–6.2months, respect-
ively. Survival data for avelumab (anti–PD-L1) in the 2 L
subgroup (median PFS and OS of 1.4 and 6.6months,
respectively) appear consistent with these studies. Subse-
quently, phase 3 trials assessing later-line treatment with
anti–PD-1/PD-L1 monotherapy in advanced GC/GEJC
were initiated. In a randomized phase 3 trial of nivolumab
vs placebo as third-line or later treatment in Asian patients
with GC/GEJC (n = 493), the ORR was 11.2% vs 0%
(P<.0001), median PFS was 1.6 vs 1.5 months (P<.0001),
and median OS was 5.3 vs 4.1 months (P<.0001), respect-
ively [13]. However, to date no improvement in OS has
been shown in studies comparing single-agent checkpoint
inhibitors with chemotherapy, such as trials of 2 L pem-
brolizumab vs paclitaxel (KEYNOTE-061) [29] and
third-line avelumab vs physician choice of chemotherapy
(JAVELIN Gastric 300) [30]. Results from phase 3 trials
assessing alternative anti–PD-1/PD-L1–based regimens in
the 1 L setting, such as switch-maintenance (sequential)
or combination (concurrent) approaches, are needed.
Available data indicate that the benefits seen with
anti–PD-1/PD-L1 antibodies in GC/GEJC may be lim-
ited to a small proportion of patients. Thus, predictive
biomarkers to identify subpopulations more likely to
respond to immunotherapy are a focus of ongoing
research [10]. In this study, clinical activity was seen
both in PD-L1+ and PD-L1− tumors including similar
ORR and PFS and a nonsignificant trend in the 1 L-mn
subgroup for longer OS in PD-L1+ tumors. It should be
noted that the PD-L1 assay used in this study differs
from those used in studies of other approved anti–PD-1/
PD-L1 antibodies. Also, in the present study, PD-L1
status was based solely on tumor cell expression,
whereas in studies of pembrolizumab in patients with
GC/GEJC, in which antitumor activity was associated
with PD-L1 expression, PD-L1 status was determined
based on expression on tumor or immune cells
(combined positive score). In addition, responses to
pembrolizumab in patients with GC/GEJC have been
associated with microsatellite instability–high/mismatch
repair–deficient status and Epstein-Barr virus status [12,
31]. In the current trial, microsatellite status was
available for only a small number of patients and findings
were inconclusive. Assessment of novel biomarkers is
planned for future avelumab studies in GC/GEJC.
Conclusion
The data in the present phase 1b study demonstrate that
avelumab administered as maintenance therapy (after
disease control with standard chemotherapy) has antitumor
activity and acceptable safety in patients with advanced
GC/GEJC, supporting further investigations of this
treatment approach.
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